β-lapachone micellar nanotherapeutics for non-small cell lung cancer therapy

Elvin Blanco, Erik A. Bey, Chalermchai Khemtong, Su Geun Yang, Jagadeesh Setti-Guthi, Huabing Chen, Chase W. Kessinger, Kevin A. Carnevale, William G. Bornmann, David A. Boothman, Jinming Gao

Research output: Contribution to journalArticle

83 Citations (Scopus)

Abstract

Lung cancer is the leading cause of cancer-related deaths with current chemotherapies lacking adequate specificity and efficacy. β-Lapachone (β-lap) is a novel anticancer drug that is bioactivated by NAD(P)H:quinone oxidoreductase 1, an enzyme found specifically overexpressed in non-small cell lung cancer (NSCLC). Herein, we report a nanotherapeutic strategy that targets NSCLC tumors in two ways: (a) pharmacodynamically through the use of a bioactivatable agent, β-lap, and (b) pharmacokinetically by using a biocompatible nano-carrier, polymeric micelles, to achieve drug stability, bioavailability, and targeted delivery. β-Lap micelles produced by a film sonication technique were small (∼30 nm), displayed core-shell architecture, and possessed favorable release kinetics. Pharmacokinetic analyses in mice bearing subcutaneous A549 lung tumors showed prolonged blood circulation (t 1/2, ∼28 h) and increased accumulation in tumors. Antitumor efficacy analyses in mice bearing subcutaneous A549 lung tumors and orthotopic Lewis lung carcinoma models showed significant tumor growth delay and increased survival. In summary, we have established a clinically viable â-lap nanomedicine platform with enhanced safety, pharmacokinetics, and antitumor efficacy for the specific treatment of NSCLC tumors.

Original languageEnglish (US)
Pages (from-to)3896-3904
Number of pages9
JournalCancer Research
Volume70
Issue number10
DOIs
StatePublished - May 15 2010

Fingerprint

Non-Small Cell Lung Carcinoma
Neoplasms
Micelles
Therapeutics
Pharmacokinetics
Nanomedicine
Drug Stability
Lewis Lung Carcinoma
Lung
Sonication
Blood Circulation
NAD
Biological Availability
Lung Neoplasms
Oxidoreductases
Safety
Drug Therapy
Enzymes
Growth
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

β-lapachone micellar nanotherapeutics for non-small cell lung cancer therapy. / Blanco, Elvin; Bey, Erik A.; Khemtong, Chalermchai; Yang, Su Geun; Setti-Guthi, Jagadeesh; Chen, Huabing; Kessinger, Chase W.; Carnevale, Kevin A.; Bornmann, William G.; Boothman, David A.; Gao, Jinming.

In: Cancer Research, Vol. 70, No. 10, 15.05.2010, p. 3896-3904.

Research output: Contribution to journalArticle

Blanco, E, Bey, EA, Khemtong, C, Yang, SG, Setti-Guthi, J, Chen, H, Kessinger, CW, Carnevale, KA, Bornmann, WG, Boothman, DA & Gao, J 2010, 'β-lapachone micellar nanotherapeutics for non-small cell lung cancer therapy', Cancer Research, vol. 70, no. 10, pp. 3896-3904. https://doi.org/10.1158/0008-5472.CAN-09-3995
Blanco, Elvin ; Bey, Erik A. ; Khemtong, Chalermchai ; Yang, Su Geun ; Setti-Guthi, Jagadeesh ; Chen, Huabing ; Kessinger, Chase W. ; Carnevale, Kevin A. ; Bornmann, William G. ; Boothman, David A. ; Gao, Jinming. / β-lapachone micellar nanotherapeutics for non-small cell lung cancer therapy. In: Cancer Research. 2010 ; Vol. 70, No. 10. pp. 3896-3904.
@article{a898d19f7498459d91746561dbf1f886,
title = "β-lapachone micellar nanotherapeutics for non-small cell lung cancer therapy",
abstract = "Lung cancer is the leading cause of cancer-related deaths with current chemotherapies lacking adequate specificity and efficacy. β-Lapachone (β-lap) is a novel anticancer drug that is bioactivated by NAD(P)H:quinone oxidoreductase 1, an enzyme found specifically overexpressed in non-small cell lung cancer (NSCLC). Herein, we report a nanotherapeutic strategy that targets NSCLC tumors in two ways: (a) pharmacodynamically through the use of a bioactivatable agent, β-lap, and (b) pharmacokinetically by using a biocompatible nano-carrier, polymeric micelles, to achieve drug stability, bioavailability, and targeted delivery. β-Lap micelles produced by a film sonication technique were small (∼30 nm), displayed core-shell architecture, and possessed favorable release kinetics. Pharmacokinetic analyses in mice bearing subcutaneous A549 lung tumors showed prolonged blood circulation (t 1/2, ∼28 h) and increased accumulation in tumors. Antitumor efficacy analyses in mice bearing subcutaneous A549 lung tumors and orthotopic Lewis lung carcinoma models showed significant tumor growth delay and increased survival. In summary, we have established a clinically viable {\^a}-lap nanomedicine platform with enhanced safety, pharmacokinetics, and antitumor efficacy for the specific treatment of NSCLC tumors.",
author = "Elvin Blanco and Bey, {Erik A.} and Chalermchai Khemtong and Yang, {Su Geun} and Jagadeesh Setti-Guthi and Huabing Chen and Kessinger, {Chase W.} and Carnevale, {Kevin A.} and Bornmann, {William G.} and Boothman, {David A.} and Jinming Gao",
year = "2010",
month = "5",
day = "15",
doi = "10.1158/0008-5472.CAN-09-3995",
language = "English (US)",
volume = "70",
pages = "3896--3904",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "10",

}

TY - JOUR

T1 - β-lapachone micellar nanotherapeutics for non-small cell lung cancer therapy

AU - Blanco, Elvin

AU - Bey, Erik A.

AU - Khemtong, Chalermchai

AU - Yang, Su Geun

AU - Setti-Guthi, Jagadeesh

AU - Chen, Huabing

AU - Kessinger, Chase W.

AU - Carnevale, Kevin A.

AU - Bornmann, William G.

AU - Boothman, David A.

AU - Gao, Jinming

PY - 2010/5/15

Y1 - 2010/5/15

N2 - Lung cancer is the leading cause of cancer-related deaths with current chemotherapies lacking adequate specificity and efficacy. β-Lapachone (β-lap) is a novel anticancer drug that is bioactivated by NAD(P)H:quinone oxidoreductase 1, an enzyme found specifically overexpressed in non-small cell lung cancer (NSCLC). Herein, we report a nanotherapeutic strategy that targets NSCLC tumors in two ways: (a) pharmacodynamically through the use of a bioactivatable agent, β-lap, and (b) pharmacokinetically by using a biocompatible nano-carrier, polymeric micelles, to achieve drug stability, bioavailability, and targeted delivery. β-Lap micelles produced by a film sonication technique were small (∼30 nm), displayed core-shell architecture, and possessed favorable release kinetics. Pharmacokinetic analyses in mice bearing subcutaneous A549 lung tumors showed prolonged blood circulation (t 1/2, ∼28 h) and increased accumulation in tumors. Antitumor efficacy analyses in mice bearing subcutaneous A549 lung tumors and orthotopic Lewis lung carcinoma models showed significant tumor growth delay and increased survival. In summary, we have established a clinically viable â-lap nanomedicine platform with enhanced safety, pharmacokinetics, and antitumor efficacy for the specific treatment of NSCLC tumors.

AB - Lung cancer is the leading cause of cancer-related deaths with current chemotherapies lacking adequate specificity and efficacy. β-Lapachone (β-lap) is a novel anticancer drug that is bioactivated by NAD(P)H:quinone oxidoreductase 1, an enzyme found specifically overexpressed in non-small cell lung cancer (NSCLC). Herein, we report a nanotherapeutic strategy that targets NSCLC tumors in two ways: (a) pharmacodynamically through the use of a bioactivatable agent, β-lap, and (b) pharmacokinetically by using a biocompatible nano-carrier, polymeric micelles, to achieve drug stability, bioavailability, and targeted delivery. β-Lap micelles produced by a film sonication technique were small (∼30 nm), displayed core-shell architecture, and possessed favorable release kinetics. Pharmacokinetic analyses in mice bearing subcutaneous A549 lung tumors showed prolonged blood circulation (t 1/2, ∼28 h) and increased accumulation in tumors. Antitumor efficacy analyses in mice bearing subcutaneous A549 lung tumors and orthotopic Lewis lung carcinoma models showed significant tumor growth delay and increased survival. In summary, we have established a clinically viable â-lap nanomedicine platform with enhanced safety, pharmacokinetics, and antitumor efficacy for the specific treatment of NSCLC tumors.

UR - http://www.scopus.com/inward/record.url?scp=77952866189&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77952866189&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-09-3995

DO - 10.1158/0008-5472.CAN-09-3995

M3 - Article

C2 - 20460521

AN - SCOPUS:77952866189

VL - 70

SP - 3896

EP - 3904

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 10

ER -